Menopause Hormone Therapy Safety Update: What Changed in 2026 (and What It Means for You)
By The HRT Index Editorial Team · Last verified:
The HRT Index is an independent comparison resource for HRT telehealth providers. This article is education, not medical advice. Any decision about hormone therapy should be made with a licensed clinician. See what we verified.
For 20 years, women were told hormone therapy was dangerous. Then the warnings started coming off the labels — and the headlines gave a lot of people whiplash.
So here is the menopause hormone therapy safety update, plain and fast: on February 12, 2026, the FDA removed the heart disease, breast cancer, and “probable dementia” risk statements from the strongest warning — the “boxed warning” — on the first six menopause hormone therapy products. It made the change because a fresh look at the science showed the old warning was too broad, especially for women who start treatment within 10 years of menopause or before age 60.
But “those warnings came off the box” and “it's safe for me” are two different sentences. The FDA kept one warning. Some risks were moved, not erased. And not every product is on the list yet. That gap — between the headline and your situation — is what the rest of this page is for.
| Your question | The fast answer |
|---|---|
| Did the FDA remove the HRT warning? | Partly. The heart disease, breast cancer, and dementia language came off the boxed warning on the first six products. |
| Does that mean HRT is safe for everyone? | No. It means the old warning was too broad. Your personal risk still matters. |
| What warning stayed? | The endometrial (uterine) cancer warning, on systemic estrogen-alone products for women who still have a uterus. |
| Who should read carefully? | Anyone with a history of breast cancer, blood clots, stroke, heart attack, liver disease, or unexplained vaginal bleeding. |
| Best next step? | Get your situation organized, then talk to a licensed clinician. Our quiz does the organizing in 60 seconds. |
Which part of this update applies to your situation?
It depends on your age, how long it's been since menopause, whether you still have a uterus, and your health history. Take our free 60-second HRT matching quiz and get a plain-language summary you can bring to a clinician.
Take the free 60-second quiz →Funding note: We may earn a commission if you choose a telehealth provider through links on this site. It doesn't change any fact on this page.
What actually changed in the menopause hormone therapy safety update?
First, two terms you'll see a lot. Hormone therapy (also called HRT, or menopause hormone therapy) means prescription estrogen, often paired with progesterone, used to ease menopause symptoms. A boxed warning(you may know it as a “black box warning”) is the most serious alert the FDA can put on a medicine — printed inside a black border at the top of the label. For two decades, hormone therapy carried one.
Here's how the change unfolded:
| Date | What happened | Why it matters |
|---|---|---|
| November 10, 2025 | The FDA asked drugmakers to remove broad boxed-warning language from menopause hormone therapy products. | This kicked off the news cycle you've been seeing. |
| February 12, 2026 | The FDA approved the first batch of updated labels — six products. | This is the concrete, on-paper change. |
The six products that changed first — verified, with the actual FDA labels
This is the part most articles skip. The FDA didn't change “all HRT” at once. It approved a first batch of six products, and at the FDA's request, 29 drug companies have submitted proposed label changes. Below are the six, what type of therapy each is, and a direct link to the real updated FDA label so you can read it yourself.
| Product | Type | What it is | Read the FDA label |
|---|---|---|---|
| Prometrium | Progesterone (systemic) | Progesterone — taken with estrogen to protect the uterus | FDA label (PDF) |
| Divigel | Estrogen, alone (systemic gel) | An estrogen gel | FDA label (PDF) |
| Cenestin | Estrogen, alone (systemic pill) | An estrogen pill | FDA label (PDF) |
| Enjuvia | Estrogen, alone (systemic pill) | An estrogen pill | FDA label (PDF) |
| Estring | Vaginal estrogen (local ring) | A low-dose vaginal estrogen ring | FDA label (PDF) |
| Bijuva | Estrogen + progesterone (systemic) | A combined pill | FDA label (PDF) |
All six had the heart disease, breast cancer, and probable dementia language removed from the boxed warning. Two quick things to know. If your medicine isn't on this list, it's probably not “left out” — its updated label may just not be approved yet, and the FDA has said more are coming. And all six are FDA-approved products; this change does not apply to compounded hormones.
Not sure where your own medication, age, or history fits? Our 60-second quiz sorts it out before you talk to a clinician.
Does this mean menopause hormone therapy is safe now?
There are three different things in this story, and people keep mixing them up. Here's each one, kept separate:
| What the FDA actually did | What government officials suggested in their comments | What the medical societies actually recommend | |
|---|---|---|---|
| Heart disease | Removed it from the boxed warning | Hinted hormone therapy might lower heart-disease risk, citing older studies | Don't start HRT to prevent heart disease. ACOG says it's not for preventing heart disease. |
| Breast cancer | Removed it from the boxed warning | Called the old warning overstated | Risk is low for younger, healthy women starting near menopause — but your own history still counts. |
| Dementia | Removed “probable dementia” — from the box and the label | Suggested a possible brain benefit | Not an approved use. Not a reason to start. |
| What it's actually for | Clears up the label so women can decide | — | Relieving symptoms and protecting bone — that's the recommended use. |
| Endometrial (uterine) cancer | Kept it in the boxed warning for systemic estrogen-alone products | — | If you have a uterus and take systemic estrogen, add progesterone to protect the lining. |
Read that middle column carefully. When officials announced this change, some went further than the science supports — talking up hormone therapy as if it prevents heart disease and dementia. The major medical groups — The Menopause Society and ACOG (the American College of Obstetricians and Gynecologists)— don't back that. Their position is steady: hormone therapy is the most effective treatment for hot flashes, night sweats, and vaginal symptoms, and it helps protect bone. It is not something to start just to prevent another disease.
We tell you this because you deserve the whole story, not the cheerful half. The update is good news. It just isn't magic news.
Not sure whether you're in the group this update reassures, or the group that needs more caution? Sort it in 60 seconds.
Take the free HRT matching quiz →No email needed to see your result.
What did NOT change — and what the risks really are
Here's exactly what moved, what was removed, and what stayed:
| Risk topic | What the FDA actually did |
|---|---|
| Heart (cardiovascular) disease | Taken out of the boxed warning. For systemic products, the information stays elsewhere in the label. |
| Breast cancer | Taken out of the boxed warning. For systemic products, the information stays elsewhere in the label. |
| Probable dementia | Removed from the boxed warning — and removed from the label entirely. |
| Endometrial (uterine) cancer | Removed from the boxed warning — except it stays for systemic estrogen-alone products. |
| “Use the lowest dose for the shortest time” | This old instruction was removed from the boxed warning. |
There's a hopeful flip side, too. For systemic products, the FDA also asked that labels add a note: starting hormone therapy can be considered for moderate-to-severe hot flashes in women under 60 or within 10 years of menopause, along with study data for women in their 50s. The label now reflects the timing science instead of a blanket scare.
Two things that genuinely did not change:
The kept warning — endometrial (uterine) cancer
If you still have a uterus and take systemic estrogen by itself, that estrogen can thicken the uterine lining over time, which raises cancer risk. That's why the FDA kept this warning, and why clinicians pair systemic estrogen with progesteronefor women with a uterus. If you've had a hysterectomy, this usually doesn't apply — ask your clinician.
The risks that moved out of the box but didn't disappear
Hormone therapy can still raise the risk of blood clots, stroke, and gallbladder disease for some people. One useful detail your clinician may bring up: estrogen through the skin — a patch or gel — may carry a lower risk of blood clots than estrogen taken as a pill. Don't assume a patch is automatically safe for you, though. Ask your clinician how the route affects your own clot and stroke risk.
How to read the specific risks people worry about most — without the panic and without the spin:
- Breast cancer.The warning language changed; the conversation didn't. For many women starting near menopause, the risk is low. But if you have a personal or family history of breast cancer, this is a talk to have with a clinician who knows your case. Don't let any website — including ours — talk you out of that. Full breakdown: HRT breast cancer risk 2026.
- Blood clots and stroke.Your personal history and the route (pill vs. patch) both matter. If you've had a clot or a stroke, say so up front.
- Dementia. Removing the warning is not proof hormone therapy prevents dementia. Please don't start it for that reason.
- Heart disease. The old warning was too broad, and starting near menopause is a different situation than starting many years later. But hormone therapy is not a heart medicine.
That's the floor of honesty for this topic. Everything good we say after this, you can trust more — because we didn't hide the hard parts.
Does the update apply to you? Who's a reasonable candidate
Doctors call this the timing hypothesis— the idea that hormone therapy looks safest and most helpful when it's started close to menopause. Two markers matter most: being under 60, and being within 10 yearsof your final period. The FDA points to studies showing that women who start in this window have a lower risk of death from any cause and fewer fractures. (That's about starting near menopause for symptoms — not starting late to chase a benefit.)
| Your situation | How to think about it |
|---|---|
| 52, severe hot flashes, no major risk history | Reasonable to discuss systemic hormone therapy with a clinician. |
| 57, 7 years since menopause, new symptoms | Still in the window — ask about timing, route, and your personal risk. |
| 64, 14 years since menopause | A more careful conversation. Not an automatic “no,” but risk gets a closer look. |
| 49, surgical menopause (ovaries removed early) | Needs its own discussion — early menopause is handled differently. |
| Mainly vaginal dryness or painful sex | A local vaginal option may be all you need (see below). |
If you can see yourself in the top rows, this update is the science finally catching up to your situation.
Who should pause and check with a clinician first?
| If this applies to you | Your best first step |
|---|---|
| Unexplained vaginal bleeding | Don't start based on any article. Get it checked — it needs an explanation first. |
| Breast cancer (personal history) | Talk to an oncologist or a menopause specialist who knows your case. |
| Prior blood clot, stroke, or heart attack | Ask a clinician about non-hormonal options and skin-based (patch/gel) routes. |
| Liver disease | This needs a clinician's review before any hormone therapy. |
| Still have a uterus | Ask whether you need progesterone alongside estrogen. |
| Not sure you're actually in menopause | Ask what evaluation makes sense before treating. |
If one of these is you, you haven't hit a dead end — you've just found the reason to start with a person, not a checkout page.
Before you book anything, see where you land.Take the free 60-second quiz to see whether you're more “reasonable to discuss” or “check with a specialist first.”
Take the free 60-second quiz →Does it apply differently to pills, patches, gels, rings, and vaginal estrogen?
| Type | What it's mainly for | The key safety note |
|---|---|---|
| Estrogen pill (oral) | Hot flashes, night sweats, whole-body symptoms | Whole-body exposure; clot/stroke history matters more here. |
| Estrogen patch | Whole-body symptoms | Skips the liver on first pass; may mean lower clot risk — ask why a patch fits you. |
| Estrogen gel or spray | Whole-body symptoms | Whole-body exposure; a steady daily dose matters. |
| Vaginal ring, cream, or tablet | Dryness, painful sex, urinary symptoms | Usually a more local question, with a different risk profile. |
| Estrogen + progesterone combo | Whole-body symptoms for women with a uterus | Pairs estrogen with the progesterone that protects the lining. |
A special word on vaginal estrogen
If your main problem is dryness, burning, or pain with sex — what doctors call GSM (genitourinary syndrome of menopause)— low-dose vaginal estrogen is often a separate, more targeted conversation than full-body hormone therapy. The Menopause Society actually welcomed the warning coming off low-dose vaginal estrogen, because that scary label had been discouraging women from a treatment it considers safe and effective for a very common problem. It's still a prescription, though, and if you have a cancer history or any unexplained bleeding, ask a clinician first.
Does this apply to compounded or “bioidentical” hormones?
Four words get tangled together. Here's each one, untangled:
| Word | What it actually means | Does the 2026 update apply? |
|---|---|---|
| FDA-approved | A finished product the FDA reviewed and approved | Yes — these are the labels that changed. |
| Bioidentical | A hormone with the same molecular structure as the ones your body makes | A description of the molecule, not an FDA stamp. Some FDA-approved products are bioidentical. |
| Compounded | Custom-mixed by a pharmacy for one person | Not automatically covered. These aren't FDA-approved finished products. |
| Custom dose | Individually prepared or adjusted | Can have a role in specific cases — but ask why an FDA-approved option wouldn't work for you. |
Two honest points that protect you. First, the word “bioidentical”is not a safety guarantee. It describes chemistry, not regulation, and there's no good evidence that compounded “bioidentical” hormones are safer or more effective than FDA-approved ones. Major groups recommend FDA-approved products as the first choice for most women. Second, compounded hormones did notbecome FDA-approved because of this update. If a provider offers you a compounded cream, troche, or pellet, it's fair to ask: would an FDA-approved option work for me, and if not, why?
None of this means compounding is “bad.” It's legal and can be the right call for specific needs. It just isn't the same thing as an FDA-approved product — and after a safety update about FDA-approved products, that difference is worth knowing. Compare compounded HRT providers.
What if you can't or don't want to use hormones?
The two newer ones work on the brain's “thermostat” pathway rather than on hormones. A few honest notes: these help with hot flashes and night sweats, but unlike estrogen they don't treat vaginal dryness, and they don't build bone (though they don't harm it either). Other medicines — certain antidepressants (like an SSRI or SNRI), gabapentin, or clonidine — are sometimes used “off-label” for hot flashes, meaning the FDA approved them for something else but a clinician may prescribe them here.
For many women who can safely take hormones, hormone therapy is still the most effective option for hot flashes. The right choice depends on your symptoms and history — which is exactly what the next sections help you sort out.
The questions to ask your clinician now
Bring this list. It turns a rushed appointment into a real plan.
- Based on my symptoms, are we talking about whole-body therapy, local vaginal therapy, or both?
- Am I under 60 or within 10 years of menopause — and how does that change things for me?
- I still have a uterus — do I need progesterone with estrogen?
- Do I have any of the “pause first” risks (cancer, clots, stroke, heart, liver, unexplained bleeding)?
- Would a pill, patch, gel, ring, or vaginal product make the most sense for my history?
- Is what you're prescribing FDA-approved, compounded, or off-label for my situation?
- What should get better, and how soon?
- What side effects should make me call you?
- How often will we re-check this?
- What non-hormonal options should I compare?
- What will this cost — with insurance, cash-pay, at the pharmacy, and for follow-ups?
- If it's working, how long can I safely stay on it?
Want this as a printable list to take with you? Take the quiz and get a version tailored to your answers — yours to bring to any appointment.
Get the free HRT conversation checklist →If you're ready to talk to someone online, what should you look for?
We earn a commission if you choose some of the providers below. That doesn't change a single fact on this page, and we're going to tell you exactly who each one is notfor. Here's a side-by-side of three solid options, with details checked on each provider's own site in June 2026:
| Provider | Best fit | Price (June 2026) | Insurance | FDA-approved vs. compounded | Key limitation |
|---|---|---|---|---|---|
| Midi Health | Insurance + clinician-first menopause care | Self-pay $250 first visit, $150 follow-ups; copay if using insurance | In-network with most PPO plans; HSA/FSA accepted | Prescribes FDA-approved hormone therapy | Can't treat Medicaid/Medi-Cal; not covered by Medicare (self-pay only) |
| Sesame | Cash-pay, no long commitment | ~$99/mo menopause subscription (confirm at checkout); medicine billed separately | Doesn't bill insurance; HSA/FSA may apply | Prescribes FDA-approved hormonal + non-hormonal options | No insurance billing; clinician availability varies by state |
| Winona | Direct-to-door care, if you understand the compounded caveat | FDA-approved: patch from $149/mo, tablets from $54/mo, progesterone from $39/mo. Compounded creams from $89/mo | Doesn't bill insurance; HSA/FSA accepted | Both: patch/tablets/progesterone are FDA-approved; body creams are compounded | Signature creams are compounded (not FDA-approved); doesn't prescribe testosterone |
If you want insurance and a clinician-first plan → Midi Health
Midi is a menopause-focused virtual clinic, available in all 50 states, in-network with most PPO plans, and it prescribes FDA-approved hormone therapy in the form that fits you (patch, pill, gel, ring, cream). The honest limitation: Midi can't treat Medicaid or Medi-Cal patients — even self-pay — and isn't covered by Medicare(though Medicare beneficiaries can pay out of pocket). If that's you, a local clinic may be the better route.
Check if Midi fits your plan →If you want a simple cash-pay visit with no long commitment → Sesame
Sesame offers a cash-pay menopause subscription (about $99/monthper its own announcement — confirm the current price at checkout) that includes video visits with a provider you choose, messaging, prescriptions sent to your local pharmacy, and basic lab work if needed. Medicine costs are separate, and Sesame doesn't bill insurance.
See Sesame's menopause options →If you want direct-to-door care → Winona, with one honest caveat
Here's the admission that matters: most of Winona's signature products — its estrogen and progesterone body creams — are compounded, not FDA-approved.On a page about an FDA-approved-product update, that's worth saying out loud. If FDA-approved finished products are your priority, Midi — or Winona's own FDA-approved line (patch at $149/month, tablets at $54/month, progesterone capsules at $39/month) — is the better fit. But because Winona runs its own compounding pharmacy and ships to your door, it can tailor formulations and offer low-friction convenience that clinic-first care doesn't — which is exactly what some women want. Just know which one you're getting. (Winona doesn't bill insurance, though HSA/FSA usually works.)
Read the full Winona review →Still weighing it all? Our quiz matches your age, timing, symptoms, and history to the route most likely to fit — and it's free. Take the quiz.
What we actually verified
What we checked:the FDA's February 12, 2026 approval, the FDA's November 10, 2025 request to drugmakers (which spells out exactly what moved, what was removed, and what stayed), and the FDA's own list of the six updated products — including the actual label PDFs, which we linked above so you can read the source yourself. We cross-checked the medical context against The Menopause Society and ACOG, and we confirmed every provider detail on each provider's own site in June 2026.
Where we drew the line:we kept medical and regulatory facts separate from provider claims, and we say plainly where government commentary went further than the medical societies recommend. We earn commissions from some telehealth providers; that doesn't change the facts here, and providers are described, not ranked or sold.
What can change (and should be re-checked):the number of products with updated labels is growing as more companies' changes clear; provider pricing, state availability, and insurance participation shift over time. We re-verify this page on a set schedule and update the date at the top.
Last verified: · By: The HRT Index Editorial Team · Re-verify schedule: monthly for 3 months, then quarterly
What to do next
| If this sounds like you | Your best next step |
|---|---|
| Healthy, under 60 or within 10 years of menopause, strong hot flashes/night sweats | Use the checklist; ask a clinician about whole-body options. |
| Mainly vaginal dryness or painful sex | Ask about local vaginal estrogen. |
| Can't or don't want to take hormones | Ask about non-hormonal options approved for hot flashes. |
| Cancer, clot, stroke, heart, or liver history | Start with a specialist or in-person clinician. |
| Not sure what kind of care fits | Take the quiz and get your clinician question list. |
You waited a long time, and you were told to be afraid for most of it. The science moved. Now you get to make a calm, informed choice — on your terms, with the full picture in hand.
Still not sure which HRT program is right for you?
Take our free 60-second matching quiz — it turns everything on this page into a personal summary you can bring to your doctor.
Take the free 60-second matching quiz →No email required. No diagnosis. No pressure.
Related reading: 2026 HRT Label Changes Explained · HRT Breast Cancer Risk 2026 · New HRT Guidelines 2026 · Compare HRT Telehealth Providers
Frequently asked questions
All answers are based on primary FDA sources, The Menopause Society, and ACOG — verified June 8, 2026. For your personal situation, talk to a licensed clinician.
- Did the FDA remove the black box warning from HRT?
- Yes, partly. On February 12, 2026, the FDA removed the heart disease, breast cancer, and "probable dementia" language from the boxed warning on the first six menopause hormone therapy products. The endometrial (uterine) cancer warning stayed on systemic estrogen-alone products.
- Does this mean HRT is safe for everyone?
- No. It means the old warning was too broad. Safety still depends on your age, how long it's been since menopause, the type and dose, whether you have a uterus, and your health history.
- What warning stayed?
- The endometrial (uterine) cancer warning remains on systemic estrogen-alone products. It matters most for women who still have a uterus, which is why estrogen is usually paired with progesterone in that case.
- Does this update apply to compounded or "bioidentical" hormones?
- Not in the same way. The update covers FDA-approved products. Compounded hormones are custom-mixed and not FDA-approved, so the FDA does not verify their strength, purity, or quality. "Bioidentical" describes the molecule, not an FDA approval.
- Is vaginal estrogen the same as whole-body HRT?
- No. Low-dose vaginal estrogen mainly treats local symptoms like dryness and painful sex, while whole-body (systemic) HRT treats symptoms like hot flashes. The FDA and major menopause groups treat them as different decisions.
- Am I too old to start HRT?
- Not automatically. The evidence is most favorable for starting under 60 or within 10 years of menopause. Starting later is a more careful conversation, so ask a clinician to review your personal risk.
- Do I need progesterone with estrogen?
- If you still have a uterus and take systemic estrogen, ask about adding progesterone to protect the uterine lining. That's exactly what the kept warning is about, so don't decide it on your own.
- Does HRT prevent dementia or heart disease?
- Don't use this update as proof that it does. The warning language changed; that's not the same as proof of prevention. Major medical groups recommend hormone therapy for symptom relief and bone protection, not disease prevention.
- What if I have a history of breast cancer?
- Don't start based on a general article. Talk to an oncologist, gynecologist, or menopause specialist who can review your specific history and your options, including non-hormonal ones.
- What are the non-hormonal options for hot flashes?
- Three medicines are FDA-approved for menopausal hot flashes: low-dose paroxetine (Brisdelle), fezolinetant (Veozah), and elinzanetant (Lynkuet). Some other medicines are used off-label, and for women who can take hormones, hormone therapy is still the most effective option for hot flashes.
Sources
- FDA — FDA Approves Labeling Changes to Menopausal Hormone Therapy Products (News Release, Feb 12, 2026)
- FDA — FDA Requests Labeling Changes…to Clarify the Benefit/Risk Considerations for Menopausal Hormone Therapies (Nov 10, 2025; current as of Feb 12, 2026)
- FDA — Menopausal Hormone Therapies with Updated Prescribing Information (updated Feb 12, 2026)
- HHS/FDA — HHS Advances Women's Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy (Nov 10, 2025)
- The Menopause Society — Comments on the FDA Announcement on Hormone Therapy (November 2025)
- ACOG — Committee Opinion 565, Hormone Therapy and Heart Disease
- Drug Topics — FDA Removes Black Box Warning on 6 Menopausal Hormone Therapy Products (Feb 12, 2026)
- FDA — Compounding and the FDA: Questions and Answers
- Provider details verified June 2026 on each provider's own site: Midi (joinmidi.com), Sesame (sesamecare.com), Winona (bywinona.com)
- FDA approvals of non-hormonal hot-flash therapies: fezolinetant (Veozah, May 2023) and elinzanetant (Lynkuet, Oct 2025); low-dose paroxetine (Brisdelle). Coverage: Pharmacy Times / AJMC / Contemporary OB/GYN (2025–2026)
About this page
Written by: The HRT Index Editorial Team — The HRT Index, an independent comparison resource for HRT telehealth providers.
Review status: Independent editorial research. Not medical advice. Any decision about hormone therapy should be made with a licensed clinician.
Last updated: · Last verified: